Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (Aducanumab) in Subjects With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

    Summary
    EudraCT number
    2019-004368-22
    Trial protocol
    DE   DK   FI   AT   PL   PT   BE   GB   IT  
    Global end of trial date
    22 Jul 2024

    Results information
    Results version number
    v1(current)
    This version publication date
    16 Feb 2025
    First version publication date
    16 Feb 2025
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    221AD304
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT04241068
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Biogen
    Sponsor organisation address
    225 Binney Street, Cambridge, United States, 02142
    Public contact
    Biogen Study Medical Director, Biogen, Biogen, clinicaltrials@biogen.com
    Scientific contact
    Biogen Study Medical Director, Biogen, Biogen, clinicaltrials@biogen.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    22 Jul 2024
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    22 Jul 2024
    Was the trial ended prematurely?
    Yes
    General information about the trial
    Main objective of the trial
    The primary objective is to evaluate the safety and tolerability of aducanumab over 100 weeks of treatment after a wash-out period imposed by discontinuation of feeder studies in participants who had previously received aducanumab (i.e. previously treated participants) or who had previously received placebo (i.e. treatment-naïve participants).
    Protection of trial subjects
    Written informed consent was obtained from each participant or participant's legally authorized representative (e.g., legal guardian), as applicable, prior to evaluations performed for eligibility. Participants or the participant's legally authorized representative were given adequate time to review the information in the informed consent/assent and were allowed to ask, and have answered, questions concerning all portions of the conduct of the study.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    02 Mar 2020
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Austria: 5
    Country: Number of subjects enrolled
    Belgium: 34
    Country: Number of subjects enrolled
    Denmark: 11
    Country: Number of subjects enrolled
    Finland: 23
    Country: Number of subjects enrolled
    France: 61
    Country: Number of subjects enrolled
    Germany: 72
    Country: Number of subjects enrolled
    Italy: 92
    Country: Number of subjects enrolled
    Netherlands: 20
    Country: Number of subjects enrolled
    Poland: 83
    Country: Number of subjects enrolled
    Portugal: 20
    Country: Number of subjects enrolled
    Spain: 100
    Country: Number of subjects enrolled
    Sweden: 23
    Country: Number of subjects enrolled
    Australia: 52
    Country: Number of subjects enrolled
    Canada: 99
    Country: Number of subjects enrolled
    Japan: 130
    Country: Number of subjects enrolled
    Korea, Republic of: 33
    Country: Number of subjects enrolled
    Switzerland: 20
    Country: Number of subjects enrolled
    Taiwan: 8
    Country: Number of subjects enrolled
    United Kingdom: 33
    Country: Number of subjects enrolled
    United States: 777
    Worldwide total number of subjects
    1696
    EEA total number of subjects
    544
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    234
    From 65 to 84 years
    1401
    85 years and over
    61

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    Participants took part in the study at the investigative sites in the United States, Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Italy, Japan, South Korea, Netherlands, Poland, Portugal, Spain, Sweden, Switzerland, Taiwan, and the United Kingdom from 02 Mar 2020 to 22 Jul 2024.

    Pre-assignment
    Screening details
    A total of 1696 participants were enrolled and treated in the core period, of which 1118 participants completed the core period. Out of the participants who completed the core period, 1041 participants entered the long-term extension (LTE) period, and 508 participants completed the LTE period.

    Period 1
    Period 1 title
    Core Treatment Period
    Is this the baseline period?
    Yes
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Arm title
    Aducanumab
    Arm description
    Participants were administered aducanumab 10 milligrams per kilogram (mg/kg) by intravenous (IV) infusions every four weeks (Q4W) for 100 weeks during the Core Treatment Period. Eligible participants continued to receive aducanumab 10 mg/kg IV infusion, Q4W, for 52 weeks during the LTE Treatment Period.
    Arm type
    Experimental

    Investigational medicinal product name
    Aducanumab
    Investigational medicinal product code
    BIIB037
    Other name
    Pharmaceutical forms
    Concentrate for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Intravenous infusion, once every 4 weeks

    Number of subjects in period 1
    Aducanumab
    Started
    1696
    Completed
    1118
    Not completed
    578
         Adverse event, serious fatal
    26
         Relocation
    4
         Reason Not Specified
    41
         Investigator Decision
    40
         Study Terminated by Sponsor
    1
         Study Visit Burden
    40
         Missing
    2
         Change of Treatment
    4
         Disease Progression
    67
         Consent Withdrawn
    143
         Loss of Capacity
    9
         Adverse event, non-fatal
    91
         Lost to follow-up
    11
         Withdrawal by Guardian/caretaker
    99
    Period 2
    Period 2 title
    LTE Period
    Is this the baseline period?
    No
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Arm title
    Aducanumab
    Arm description
    Participants were administered aducanumab 10 milligrams per kilogram (mg/kg) by intravenous (IV) infusions every four weeks (Q4W) for 100 weeks during the Core Treatment Period. Eligible participants continued to receive aducanumab 10 mg/kg IV infusion, Q4W, for 52 weeks during the LTE Treatment Period.
    Arm type
    Experimental

    Investigational medicinal product name
    Aducanumab
    Investigational medicinal product code
    BIIB037
    Other name
    Pharmaceutical forms
    Concentrate for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Intravenous infusion, once every 4 weeks

    Number of subjects in period 2
    Aducanumab
    Started
    1041
    Completed
    508
    Not completed
    533
         Adverse event, serious fatal
    8
         Relocation
    6
         Reason Not Specified
    65
         Investigator Decision
    12
         Site Terminated by Sponsor
    26
         Study Terminated by Sponsor
    276
         Study Visit Burden
    10
         Disease Progression
    11
         Change of Treatment
    1
         Consent Withdrawn
    71
         Loss of Capacity
    2
         Adverse event, non-fatal
    19
         Lost to follow-up
    7
         Withdrawal by Guardian/caretaker
    19

    Baseline characteristics

    Close Top of page
    Subject analysis sets

    Subject analysis set title
    Aducanumab
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Participants were administered aducanumab 10 milligram per kilograms (mg/kg) by intravenous (IV) infusions every four weeks (Q4W) for 100 weeks during the Core Treatment Period. Eligible participants continued to receive aducanumab 10 mg/kg IV infusion, Q4W, for 52 weeks during the LTE Treatment Period.

    Subject analysis set title
    Aducanumab
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Participants were administered aducanumab 10 mg/kg by IV infusions, Q4W for 100 weeks during the Core Treatment Period.

    Subject analysis sets values
    Aducanumab Aducanumab
    Number of subjects
    1696
    1696
    Age Categorical
    Units: Subjects
    Age continuous
    Modified Intent-to-treat (mITT) population included all participants who had received at least one dose of aducanumab in the study 221AD304.
    Units: years
        arithmetic mean (standard deviation)
    73.1 ( 7.34 )
    0 ( 0 )
    Gender categorical
    Units: Subjects
        Male
    815
    0
        Female
    881
    0
    Race
    Units: Subjects
        Asian
    185
    0
        Black or African American
    8
    0
        White
    1399
    0
        Not Reported Due to Confidentiality Regulations
    55
    0
        Other
    3
    0
        Unknown
    46
    0
    Ethnicity
    Units: Subjects
        Hispanic or Latino
    61
    0
        Not Hispanic or Latino
    1562
    0
        Not Reported Due to Confidentiality Regulations
    73
    0

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Aducanumab
    Reporting group description
    Participants were administered aducanumab 10 milligrams per kilogram (mg/kg) by intravenous (IV) infusions every four weeks (Q4W) for 100 weeks during the Core Treatment Period. Eligible participants continued to receive aducanumab 10 mg/kg IV infusion, Q4W, for 52 weeks during the LTE Treatment Period.
    Reporting group title
    Aducanumab
    Reporting group description
    Participants were administered aducanumab 10 milligrams per kilogram (mg/kg) by intravenous (IV) infusions every four weeks (Q4W) for 100 weeks during the Core Treatment Period. Eligible participants continued to receive aducanumab 10 mg/kg IV infusion, Q4W, for 52 weeks during the LTE Treatment Period.

    Subject analysis set title
    Aducanumab
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Participants were administered aducanumab 10 milligram per kilograms (mg/kg) by intravenous (IV) infusions every four weeks (Q4W) for 100 weeks during the Core Treatment Period. Eligible participants continued to receive aducanumab 10 mg/kg IV infusion, Q4W, for 52 weeks during the LTE Treatment Period.

    Subject analysis set title
    Aducanumab
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Participants were administered aducanumab 10 mg/kg by IV infusions, Q4W for 100 weeks during the Core Treatment Period.

    Primary: Core Treatment Period: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs

    Close Top of page
    End point title
    Core Treatment Period: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs [1]
    End point description
    AE=any untoward medical occurrence in participant/clinical investigation participant administered pharmaceutical product,that does not necessarily have causal relationship with this treatment.AE can be any unfavorable & unintended sign(including an abnormal laboratory finding),symptom/disease temporally associated with use of medicinal(investigational) product,whether or not related to medicinal(investigational)product. SAE=any untoward medical occurrence that at any dose results in death,is life-threatening event,requires inpatient hospitalization/prolongation of existing hospitalization,results in significant disability/incapacity/congenital anomaly,is medically important event.TEAE/Serious TEAEs=any AE that has onset date and time that is on/after date and time of first dose of study treatment/that has worsened after date and time of first dose of study treatment.Safety population for core period=all participants who had received atleast 1 dose of aducanumab in core period.
    End point type
    Primary
    End point timeframe
    From the first dose of study drug to end of follow-up (up to Week 118)
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Only descriptive statistics were planned for this endpoint.
    End point values
    Aducanumab
    Number of subjects analysed
    1696
    Units: participants
        TEAEs
    1549
        Serious TEAEs
    318
    No statistical analyses for this end point

    Primary: Core Treatment Period: Number of Participants with AEs Leading to Treatment Discontinuation (TD) and Study Withdrawal (SW)

    Close Top of page
    End point title
    Core Treatment Period: Number of Participants with AEs Leading to Treatment Discontinuation (TD) and Study Withdrawal (SW) [2]
    End point description
    An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. The safety population included all participants who had received at least one dose of aducanumab in the core period.
    End point type
    Primary
    End point timeframe
    From the first dose of study drug to end of follow-up (up to Week 118)
    Notes
    [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Only descriptive statistics were planned for this endpoint.
    End point values
    Aducanumab
    Number of subjects analysed
    1696
    Units: participants
        AEs leading to TD
    168
        AEs leading to SW
    129
    No statistical analyses for this end point

    Primary: Core Treatment Period: Number of Participants with Amyloid-Related Imaging Abnormality-Edema (ARIA-E)

    Close Top of page
    End point title
    Core Treatment Period: Number of Participants with Amyloid-Related Imaging Abnormality-Edema (ARIA-E) [3]
    End point description
    Number of participants diagnosed with ARIA edema are reported. The safety magnetic resonance imaging (MRI) population for the core period included all participants who had received at least one dose of aducanumab in the core period and had at least one post-baseline MRI assessment in the core period. Here, ‘overall number of participants analysed’ signifies the number of participants with data available for outcome measure analysis.
    End point type
    Primary
    End point timeframe
    Up to Week 118
    Notes
    [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Only descriptive statistics were planned for this endpoint.
    End point values
    Aducanumab
    Number of subjects analysed
    1656
    Units: participants
    422
    No statistical analyses for this end point

    Primary: Core Treatment Period: Number of Participants with Amyloid-Related Imaging Abnormality- Hemorrhage or Superficial Siderosis (ARIA-H)

    Close Top of page
    End point title
    Core Treatment Period: Number of Participants with Amyloid-Related Imaging Abnormality- Hemorrhage or Superficial Siderosis (ARIA-H) [4]
    End point description
    Number of participants diagnosed with ARIA hemmorrhage or superficial siderosis are reported. The safety MRI population for the core period included all participants who had received at least one dose of aducanumab in the core period and had at least one post-baseline MRI assessment in the core period. Here, ‘overall number of participants analysed’ signifies the number of participants with data available for outcome measure analysis.
    End point type
    Primary
    End point timeframe
    Up to Week 118
    Notes
    [4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Only descriptive statistics were planned for this endpoint.
    End point values
    Aducanumab
    Number of subjects analysed
    1656
    Units: participants
    505
    No statistical analyses for this end point

    Primary: Core Treatment Period: Number of Participants With Positive Antidrug Antibodies (ADAs) in Serum

    Close Top of page
    End point title
    Core Treatment Period: Number of Participants With Positive Antidrug Antibodies (ADAs) in Serum [5]
    End point description
    The presence of serum ADAs was determined using a validated assay. A standard 3-tiered approach was used including screening assay, confirmatory assay, and titration assay. The number of participants with a positive response to ADAs are reported. The immunogenicity population for the core period included all participants who had received at least one dose of aducanumab in the core period and had at least one post-dose sample evaluated for immunogenicity in the core period. Here, ‘overall number of participants analysed’ signifies the number of participants with data available for outcome measure analysis.
    End point type
    Primary
    End point timeframe
    Up to Week 102
    Notes
    [5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Only descriptive statistics were planned for this endpoint.
    End point values
    Aducanumab
    Number of subjects analysed
    1595
    Units: participants
    19
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    From first dose of study drug up to last follow-up visit (up to Week 170)
    Adverse event reporting additional description
    The safety population included all participants who had received at least one dose of aducanumab in this study (221AD304).
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    26.1
    Reporting groups
    Reporting group title
    Aducanumab
    Reporting group description
    Participants were administered aducanumab 10 mg/kg by IV infusions, Q4W for 100 weeks during the Core Treatment Period. Eligible participants continued to receive aducanumab 10 mg/kg IV infusion, Q4W, for 52 weeks during the LTE Treatment Period.

    Serious adverse events
    Aducanumab
    Total subjects affected by serious adverse events
         subjects affected / exposed
    416 / 1696 (24.53%)
         number of deaths (all causes)
    37
         number of deaths resulting from adverse events
    0
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Adenocarcinoma pancreas
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Atypical fibroxanthoma
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Basal cell carcinoma
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Benign nipple neoplasm
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Bladder cancer
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Bladder transitional cell carcinoma
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Breast cancer
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Endometrial cancer stage i
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Follicular lymphoma
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Gastric cancer
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Gastric cancer recurrent
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Glioblastoma
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Adenocarcinoma of colon
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Glioblastoma multiforme
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Ovarian cancer
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Invasive ductal breast carcinoma
         subjects affected / exposed
    3 / 1696 (0.18%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    Invasive lobular breast carcinoma
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Invasive papillary breast carcinoma
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Lung adenocarcinoma
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Lung adenocarcinoma stage iii
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Lung cancer metastatic
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Lung neoplasm malignant
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Lung squamous cell carcinoma stage iii
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Malignant melanoma
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Malignant peritoneal neoplasm
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Meningioma
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Metastatic bronchial carcinoma
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Metastatic uterine cancer
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Intraductal papillary mucinous neoplasm
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Pancreatic carcinoma
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Prostate cancer
         subjects affected / exposed
    5 / 1696 (0.29%)
         occurrences causally related to treatment / all
    0 / 6
         deaths causally related to treatment / all
    0 / 0
    Prostatic adenoma
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Squamous cell carcinoma of lung
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Squamous cell carcinoma of the tongue
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Uterine cancer
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Waldenstrom\'s macroglobulinaemia
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Vascular disorders
    Hypertensive crisis
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Aortic stenosis
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Deep vein thrombosis
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Hypertension
         subjects affected / exposed
    3 / 1696 (0.18%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    Hypotension
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Orthostatic hypotension
         subjects affected / exposed
    3 / 1696 (0.18%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    Internal haemorrhage
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    General disorders and administration site conditions
    Pyrexia
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Asthenia
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Chest pain
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Death
         subjects affected / exposed
    4 / 1696 (0.24%)
         occurrences causally related to treatment / all
    0 / 4
         deaths causally related to treatment / all
    0 / 4
    Gait disturbance
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    General physical health deterioration
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 1
    Malaise
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Multiple organ dysfunction syndrome
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Non-cardiac chest pain
         subjects affected / exposed
    4 / 1696 (0.24%)
         occurrences causally related to treatment / all
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    Sudden death
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Systemic inflammatory response syndrome
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Immune system disorders
    Anaphylactic reaction
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    Anaphylactic shock
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Social circumstances
    Loss of personal independence in daily activities
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Reproductive system and breast disorders
    Benign prostatic hyperplasia
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Breast haematoma
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Breast swelling
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Colpocele
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Female genital tract fistula
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Prostatitis
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Choking
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Acute respiratory failure
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Atelectasis
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Chronic obstructive pulmonary disease
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 1
    Dyspnoea
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Hypoxia
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Obstructive sleep apnoea syndrome
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Pulmonary embolism
         subjects affected / exposed
    10 / 1696 (0.59%)
         occurrences causally related to treatment / all
    0 / 10
         deaths causally related to treatment / all
    0 / 1
    Pulmonary fibrosis
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Respiratory failure
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Psychiatric disorders
    Aggression
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Agitation
         subjects affected / exposed
    10 / 1696 (0.59%)
         occurrences causally related to treatment / all
    0 / 11
         deaths causally related to treatment / all
    0 / 0
    Behaviour disorder
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Confusional state
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Delirium
         subjects affected / exposed
    3 / 1696 (0.18%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    Disorientation
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Mental status changes
         subjects affected / exposed
    7 / 1696 (0.41%)
         occurrences causally related to treatment / all
    1 / 7
         deaths causally related to treatment / all
    0 / 0
    Psychiatric decompensation
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Somatic symptom disorder
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Suicidal ideation
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Suicide attempt
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Tic
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Neuropsychological symptoms
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Investigations
    Colonoscopy
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Injury, poisoning and procedural complications
    Cervical vertebral fracture
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Accidental overdose
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Acetabulum fracture
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Ankle fracture
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Arthropod sting
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Cardiac valve replacement complication
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Accident
         subjects affected / exposed
    3 / 1696 (0.18%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    Concussion
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Multiple fractures
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Craniocerebral injury
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Fall
         subjects affected / exposed
    59 / 1696 (3.48%)
         occurrences causally related to treatment / all
    1 / 62
         deaths causally related to treatment / all
    0 / 1
    Femoral neck fracture
         subjects affected / exposed
    14 / 1696 (0.83%)
         occurrences causally related to treatment / all
    1 / 14
         deaths causally related to treatment / all
    0 / 0
    Femur fracture
         subjects affected / exposed
    6 / 1696 (0.35%)
         occurrences causally related to treatment / all
    0 / 6
         deaths causally related to treatment / all
    0 / 0
    Forearm fracture
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Foreign body in urogenital tract
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Fractured sacrum
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Hand fracture
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Head injury
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Hip fracture
         subjects affected / exposed
    7 / 1696 (0.41%)
         occurrences causally related to treatment / all
    0 / 7
         deaths causally related to treatment / all
    0 / 0
    Humerus fracture
         subjects affected / exposed
    3 / 1696 (0.18%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    Incisional hernia
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Lumbar vertebral fracture
         subjects affected / exposed
    3 / 1696 (0.18%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    Contusion
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Patella fracture
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Ulna fracture
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Post procedural haemorrhage
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Procedural pain
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Procedural pneumothorax
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Radius fracture
         subjects affected / exposed
    3 / 1696 (0.18%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    Rib fracture
         subjects affected / exposed
    4 / 1696 (0.24%)
         occurrences causally related to treatment / all
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    Road traffic accident
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Spinal compression fracture
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Spinal fracture
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Subdural haematoma
         subjects affected / exposed
    7 / 1696 (0.41%)
         occurrences causally related to treatment / all
    0 / 7
         deaths causally related to treatment / all
    0 / 0
    Subdural haemorrhage
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Thoracic vertebral fracture
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Tibia fracture
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Tooth injury
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Toxicity to various agents
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Traumatic intracranial haemorrhage
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Pelvic fracture
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Urinary retention postoperative
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Wrong product administered
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Cardiac disorders
    Acute coronary syndrome
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Acute myocardial infarction
         subjects affected / exposed
    4 / 1696 (0.24%)
         occurrences causally related to treatment / all
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    Atrial fibrillation
         subjects affected / exposed
    13 / 1696 (0.77%)
         occurrences causally related to treatment / all
    0 / 14
         deaths causally related to treatment / all
    0 / 0
    Atrioventricular block
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Atrioventricular block complete
         subjects affected / exposed
    5 / 1696 (0.29%)
         occurrences causally related to treatment / all
    0 / 5
         deaths causally related to treatment / all
    0 / 0
    Bradyarrhythmia
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Bradycardia
         subjects affected / exposed
    3 / 1696 (0.18%)
         occurrences causally related to treatment / all
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    Cardiac arrest
         subjects affected / exposed
    7 / 1696 (0.41%)
         occurrences causally related to treatment / all
    0 / 7
         deaths causally related to treatment / all
    0 / 7
    Cardiac failure
         subjects affected / exposed
    4 / 1696 (0.24%)
         occurrences causally related to treatment / all
    0 / 4
         deaths causally related to treatment / all
    0 / 1
    Cardiac failure chronic
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Atrioventricular block second degree
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Cardiac failure congestive
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Cardio-respiratory arrest
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Coronary artery occlusion
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Stress cardiomyopathy
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Myocardial infarction
         subjects affected / exposed
    4 / 1696 (0.24%)
         occurrences causally related to treatment / all
    0 / 4
         deaths causally related to treatment / all
    0 / 2
    Pericarditis
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Sinus node dysfunction
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Left ventricular failure
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Supraventricular tachycardia
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Ventricle rupture
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Ventricular extrasystoles
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Ventricular tachycardia
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Tachycardia
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Nervous system disorders
    Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits
         subjects affected / exposed
    3 / 1696 (0.18%)
         occurrences causally related to treatment / all
    3 / 3
         deaths causally related to treatment / all
    0 / 0
    Amyloid related imaging abnormality-oedema/effusion
         subjects affected / exposed
    9 / 1696 (0.53%)
         occurrences causally related to treatment / all
    8 / 9
         deaths causally related to treatment / all
    0 / 0
    Autonomic nervous system imbalance
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Bell\'s palsy
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Carotid artery occlusion
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Carotid artery stenosis
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Cerebellar haematoma
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Cerebellar stroke
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Idiopathic generalised epilepsy
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Cerebral infarction
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Cerebral ischaemia
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Cerebrovascular accident
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    Dementia alzheimer\'s type
         subjects affected / exposed
    4 / 1696 (0.24%)
         occurrences causally related to treatment / all
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    Dementia of the alzheimer's type, with delirium
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Dementia with lewy bodies
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Dizziness
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Embolic stroke
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Encephalopathy
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Epilepsy
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Generalised tonic-clonic seizure
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Haemorrhagic cerebral infarction
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Haemorrhagic stroke
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Cerebral haemorrhage
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Metabolic encephalopathy
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Mental impairment
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Presyncope
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Psychomotor hyperactivity
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Seizure
         subjects affected / exposed
    13 / 1696 (0.77%)
         occurrences causally related to treatment / all
    6 / 14
         deaths causally related to treatment / all
    0 / 1
    Small fibre neuropathy
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Status epilepticus
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Subarachnoid haemorrhage
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Syncope
         subjects affected / exposed
    23 / 1696 (1.36%)
         occurrences causally related to treatment / all
    1 / 24
         deaths causally related to treatment / all
    0 / 1
    Transient global amnesia
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Transient ischaemic attack
         subjects affected / exposed
    8 / 1696 (0.47%)
         occurrences causally related to treatment / all
    0 / 8
         deaths causally related to treatment / all
    0 / 0
    Ischaemic cerebral infarction
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Ischaemic stroke
         subjects affected / exposed
    9 / 1696 (0.53%)
         occurrences causally related to treatment / all
    0 / 9
         deaths causally related to treatment / all
    0 / 0
    Loss of consciousness
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Myelopathy
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Blood and lymphatic system disorders
    Normocytic anaemia
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Anaemia vitamin b12 deficiency
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Ear and labyrinth disorders
    Vertigo positional
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Eye disorders
    Cataract
         subjects affected / exposed
    3 / 1696 (0.18%)
         occurrences causally related to treatment / all
    0 / 5
         deaths causally related to treatment / all
    0 / 0
    Retinal detachment
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Gastrointestinal disorders
    Duodenal perforation
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Abdominal hernia
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Anorectal disorder
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Ascites
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Colitis
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Colitis ischaemic
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Constipation
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Diverticulum intestinal haemorrhagic
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Duodenal ulcer
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Duodenal ulcer haemorrhage
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Enteritis
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Faecaloma
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Gastrointestinal disorder
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Gastrointestinal haemorrhage
         subjects affected / exposed
    3 / 1696 (0.18%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    Obstructive pancreatitis
         subjects affected / exposed
    3 / 1696 (0.18%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    Haemorrhoidal haemorrhage
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Inguinal hernia
         subjects affected / exposed
    5 / 1696 (0.29%)
         occurrences causally related to treatment / all
    0 / 5
         deaths causally related to treatment / all
    0 / 0
    Intestinal ischaemia
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Intestinal obstruction
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Large intestine polyp
         subjects affected / exposed
    3 / 1696 (0.18%)
         occurrences causally related to treatment / all
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    Leukoplakia oral
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Gastrooesophageal reflux disease
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Oesophageal motility disorder
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Rectal prolapse
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Small intestinal obstruction
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Small intestinal perforation
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Umbilical hernia
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Vomiting
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Pancreatitis
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Hepatobiliary disorders
    Bile duct stone
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Biliary colic
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Cholecystitis
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Cholecystitis acute
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Cholelithiasis
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Skin and subcutaneous tissue disorders
    Angioedema
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Leukoplakia
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Renal and urinary disorders
    Chronic kidney disease
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Acute kidney injury
         subjects affected / exposed
    4 / 1696 (0.24%)
         occurrences causally related to treatment / all
    0 / 4
         deaths causally related to treatment / all
    0 / 1
    End stage renal disease
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Hydronephrosis
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Nephrolithiasis
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Renal colic
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Urinary retention
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Haematuria
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Musculoskeletal and connective tissue disorders
    Osteoporotic fracture
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Arthralgia
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Back pain
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Chest wall haematoma
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Chondrocalcinosis
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Lumbar spinal stenosis
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Muscular weakness
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Osteoarthritis
         subjects affected / exposed
    3 / 1696 (0.18%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    Systemic lupus erythematosus
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Polymyalgia rheumatica
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Infections and infestations
    Cat scratch disease
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Acute sinusitis
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Appendicitis
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Appendicitis perforated
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Bacterial infection
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Bronchitis
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Cellulitis
         subjects affected / exposed
    5 / 1696 (0.29%)
         occurrences causally related to treatment / all
    0 / 5
         deaths causally related to treatment / all
    0 / 0
    Lower respiratory tract infection
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Covid-19
         subjects affected / exposed
    16 / 1696 (0.94%)
         occurrences causally related to treatment / all
    0 / 16
         deaths causally related to treatment / all
    0 / 3
    Covid-19 pneumonia
         subjects affected / exposed
    8 / 1696 (0.47%)
         occurrences causally related to treatment / all
    0 / 8
         deaths causally related to treatment / all
    0 / 2
    Cystitis
         subjects affected / exposed
    3 / 1696 (0.18%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 1
    Diverticulitis
         subjects affected / exposed
    4 / 1696 (0.24%)
         occurrences causally related to treatment / all
    0 / 4
         deaths causally related to treatment / all
    0 / 1
    Diverticulitis intestinal perforated
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Enterococcal sepsis
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Enterovirus infection
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Escherichia urinary tract infection
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Gastroenteritis
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Gingivitis
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Infective exacerbation of bronchiectasis
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Influenza
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Klebsiella urinary tract infection
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Clostridium difficile colitis
         subjects affected / exposed
    4 / 1696 (0.24%)
         occurrences causally related to treatment / all
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    Meningitis
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Nasopharyngitis
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Neuroborreliosis
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Neutropenic sepsis
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Osteomyelitis
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Pneumonia
         subjects affected / exposed
    10 / 1696 (0.59%)
         occurrences causally related to treatment / all
    0 / 11
         deaths causally related to treatment / all
    0 / 2
    Pneumonia aspiration
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 1
    Post procedural infection
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Pyelonephritis
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Pyelonephritis acute
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Respiratory tract infection
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Sepsis
         subjects affected / exposed
    3 / 1696 (0.18%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 2
    Septic shock
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Staphylococcal sepsis
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Streptococcal infection
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Subdural abscess
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Tracheobronchitis
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Urinary tract infection
         subjects affected / exposed
    4 / 1696 (0.24%)
         occurrences causally related to treatment / all
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    Urinary tract infection pseudomonal
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Urosepsis
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 1
    Metabolism and nutrition disorders
    Decreased appetite
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Dehydration
         subjects affected / exposed
    4 / 1696 (0.24%)
         occurrences causally related to treatment / all
    0 / 4
         deaths causally related to treatment / all
    0 / 1
    Failure to thrive
         subjects affected / exposed
    2 / 1696 (0.12%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Hyponatraemia
         subjects affected / exposed
    3 / 1696 (0.18%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    Hypovolaemia
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Malnutrition
         subjects affected / exposed
    1 / 1696 (0.06%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Aducanumab
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    1351 / 1696 (79.66%)
    Investigations
    Weight decreased
         subjects affected / exposed
    91 / 1696 (5.37%)
         occurrences all number
    98
    Injury, poisoning and procedural complications
    Fall
         subjects affected / exposed
    355 / 1696 (20.93%)
         occurrences all number
    543
    Contusion
         subjects affected / exposed
    92 / 1696 (5.42%)
         occurrences all number
    104
    Vascular disorders
    Hypertension
         subjects affected / exposed
    130 / 1696 (7.67%)
         occurrences all number
    139
    Nervous system disorders
    Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits
         subjects affected / exposed
    443 / 1696 (26.12%)
         occurrences all number
    710
    Dizziness
         subjects affected / exposed
    146 / 1696 (8.61%)
         occurrences all number
    189
    Amyloid related imaging abnormality-oedema/effusion
         subjects affected / exposed
    424 / 1696 (25.00%)
         occurrences all number
    717
    Superficial siderosis of central nervous system
         subjects affected / exposed
    232 / 1696 (13.68%)
         occurrences all number
    333
    Headache
         subjects affected / exposed
    246 / 1696 (14.50%)
         occurrences all number
    441
    General disorders and administration site conditions
    Fatigue
         subjects affected / exposed
    98 / 1696 (5.78%)
         occurrences all number
    115
    Gastrointestinal disorders
    Constipation
         subjects affected / exposed
    87 / 1696 (5.13%)
         occurrences all number
    93
    Diarrhoea
         subjects affected / exposed
    130 / 1696 (7.67%)
         occurrences all number
    170
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    103 / 1696 (6.07%)
         occurrences all number
    121
    Psychiatric disorders
    Anxiety
         subjects affected / exposed
    104 / 1696 (6.13%)
         occurrences all number
    116
    Musculoskeletal and connective tissue disorders
    Back pain
         subjects affected / exposed
    140 / 1696 (8.25%)
         occurrences all number
    162
    Arthralgia
         subjects affected / exposed
    158 / 1696 (9.32%)
         occurrences all number
    193
    Infections and infestations
    Covid-19
         subjects affected / exposed
    427 / 1696 (25.18%)
         occurrences all number
    459
    Nasopharyngitis
         subjects affected / exposed
    107 / 1696 (6.31%)
         occurrences all number
    130
    Urinary tract infection
         subjects affected / exposed
    122 / 1696 (7.19%)
         occurrences all number
    181

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    26 Aug 2020
    Safety data from the Phase 3 Studies 221AD301 and 221AD302 updated and with additional supporting information on the efficacy of aducanumab at 10 mg/kg dosing from the Phase 1b study, Study 221AD103.
    07 Mar 2021
    Text describing the rescreening criteria was revised.
    18 Jan 2022
    Added a 52-week LTE period (13 additional doses) to the ongoing study.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    The study was terminated prematurely based on the sponsor's decision.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 06:18:11 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA